Phân tích sản phẩm tùy chọn
Khi được bạn cho phép, chúng tôi sử dụng phân tích giới hạn, chú trọng quyền riêng tư để hiểu hành trình nghiên cứu nào hiệu quả. Chúng tôi không dùng trình theo dõi quảng cáo hoặc ghi lại phiên. Bạn có thể thay đổi lựa chọn này trong Tùy chọn. Đọc Chính sách quyền riêng tư.
The primary opportunity that could accelerate earnings recovery is a faster-than-expected reconciliation of state Medicaid reimbursement rates with actual member acuity.
State Medicaid agencies update reimbursement rates by only 4% while medical cost inflation remains persistent at 5%.
We initiate coverage on Molina Healthcare Inc. with a Sell rating and a Fair value of USD 153.64, representing 26.6% downside from the report-date price of USD 209.19 as of 2026-10-14.4
Our Sell rating indicates that Molina Healthcare shares are materially overvalued relative to their fundamental earnings power, advising investors to reduce exposure or exit positions. While the company operates a specialized government-sponsored healthcare franchise, current market valuation prices in an aggressive and frictionless operational turnaround that understates regulatory rate-setting friction and structural volume headwinds across managed Medicaid.5
The report was prepared at a share price of USD 209.19 as of 2026-10-14. This price sits 36.2% above our Fair value of USD 153.64 and exceeds even our Potential value of USD 188.58. Trading at a forward price-to-earnings multiple of 18.9x, Molina commands a substantial premium to diversified managed care peers such as Cigna at 8.44x and CVS Health at 10.26x, leaving no for operational execution missteps.
The central risk confronting the business is persistent underwriting margin compression from lagging state Medicaid rate updates. Management guided full-year 2026 Medicaid rates at 4% against medical cost trends of 5%. If state capitation rate increases fail to bridge this 100-basis-point deficit and post-redetermination member acuity drives the Medicaid Medical Care Ratio above 93.5%, annual pretax earnings would contract by approximately USD 350M to USD 400M, while ongoing cumulative Medicaid enrollment runoff of 8% to 9% erodes fixed administrative cost absorption.5
Conversely, the principal operational catalyst that could support earnings recovery is the combination of Medicaid rate catch-up and non-recurring loss elimination. Management is exiting discontinued Medicare Advantage products ($1.00 per share 2026 drag) and pruning individual Marketplace exchanges to eliminate a $0.75 per share loss. Coupled with robust outperformance in Medicare duals ($1.25 per share contribution on $5B revenue), operating margin expansion toward normalized levels could lift earnings per share toward consensus FY2027 expectations of $8.55. However, even achieving Potential value of USD 188.58 remains well below the report-date price of USD 209.19.145
State healthcare agencies face substantial administrative, clinical, and logistical friction when transitioning vulnerable Medicaid populations between managed care organizations, providing incumbent advantage during contract renewals.5
Molina maintains a disciplined operating cost structure, guiding full-year G&A expenses to 6.4% of revenue, which enables the company to bid competitively in state procurements while preserving positive underwriting margins.5
In an industry upcycle, state Medicaid agencies grant generous prospective capitation rate increases that exceed medical loss trends, Medicaid redetermination attrition reverses into net membership gains, individual exchange enrollment expands profitably, and commercial peers avoid aggressive procurement price discounting.
Sell: At USD 209.19 as of 2026-10-14, Molina Healthcare trades at an unjustified 36.2% premium over our Fair value of USD 153.64, as the market prices in rapid margin recovery while ignoring regulatory rate lags, individual exchange adverse selection, and ongoing Medicaid volume contraction.4
Molina Healthcare, Inc. is a managed care company providing healthcare services to individuals under government-funded programs, primarily Medicaid, Medicare, and state health insurance Marketplace exchanges. The company operates through three principal reportable segments: Medicaid, Medicare, and Marketplace, serving eligible low-income families and individuals, aged, blind, and disabled beneficiaries, and dual-eligible members across multiple states.
Through its specialized health plans, Molina delivers comprehensive healthcare management, coordinating physical health, behavioral health, and pharmacy benefits with contracted hospital and clinical provider networks. Operating with a disciplined administrative model, the company leverages state-sponsored Medicaid contract awards, Medicare Advantage Special Needs Plans, and qualified health plans on state and federal exchanges.
Our deterministic stress test evaluates the financial impact of compound operational headwinds: a persistent 100 bps rate-trend deficit in Medicaid, an extended -$0.50 per share loss in individual Marketplace exchanges, and a valuation de-rating toward commercial managed care peers CI (8.44x forward P/E) and CVS (10.26x forward P/E). Under these stress conditions, operating margin remains constrained near 2.5% rather than normalizing to 3.2%, driving earnings per share toward the consensus low of $3.31 in FY2027 and pushing fair value down toward the low valuation boundary of USD 110.19, representing a 47.3% decline from the report-date price of USD 209.19.
Our Bear scenario contemplates a severe downside trajectory where state Medicaid rate increases persistently lag medical cost inflation, keeping medical care ratios elevated and locking in underwriting deficits. Adverse selection in individual exchange plans deepens as healthy lives defect to competitors, and post-redetermination enrollment attrition accelerates across core operating states. In this environment, operating margins remain depressed, parent cash extractions are constrained, and valuation multiples de-rate toward commercial managed care peers. Disconfirmation of this downside path would occur if state health authorities implement retroactive rate enhancements or if medical cost trends decelerate sharply.
Management confirmed that state Medicaid rate updates are tracking at 4% against medical cost trends of 5%. Failure to close this 100 bps deficit widens underwriting losses and compresses annual pretax earnings by $350M to $400M, impairing normalized operating margins.5
Năm diễn biến có thể làm suy yếu luận điểm đầu tư của chúng tôi.
Signals that state reimbursement rate updates of 4% are failing to cover 5% medical cost trends, widening the underwriting deficit by $350M-$400M and breaking the 1.2% Medicaid margin floor.
Hiện tại:92.9% (FY2026 full-year guidance)
Cảnh báo nếu>93.5% for two consecutive quarters
Molina Healthcare holds a Narrow economic moat supported by switching costs in government managed care contracts and localized scale economies. The company specializes in administering complex government-sponsored healthcare programs, primarily Medicaid and Medicare dual-eligible plans. Over decades of operation, Molina has built deep integration with state social service departments and dense regional provider networks, creating institutional barriers to entry for commercial insurers lacking government program specialization.
While these structural factors generate attractive returns on capital during normalized underwriting periods, the moat cannot be classified as Wide. State Medicaid agencies periodically re-procure managed care contracts through competitive RFP processes, creating renewal risk that can instantly eliminate substantial revenue streams. Additionally, state regulatory caps on managed care operating margins limit long-term pricing power and excess economic rents.
Normalized return on invested capital exceeds Molina's moderate cost of equity of 8.66% (WACC of 7.64%), generating positive economic profit across complete underwriting cycles. Nevertheless, state margin corridors and periodic rebids constrain excess return generation over extended horizons.2
Each lens answers a different valuation question. Only included lenses set Fair value; floors and diagnostics provide context.
The highlighted cell is Fair value when every assumption sits at its base level ($153.64). Each row and column shows what Fair value becomes when one assumption moves.
A free-cash-flow drop test is not available in this run; use the discount-rate and terminal-growth grid as the primary valuation pressure test.
Our Base scenario projects a target value of $153.64, representing an implied return of -26.6% from $209.19 with an assigned probability of 55.0%. This scenario underwrites a measured post-trough recovery where state Medicaid rate adjustments gradually align with medical cost trends, allowing operating margins to normalize from FY2026 trough levels toward historical averages by FY2030. Discontinued product drags roll off into FY2027 as planned, and Medicare duals expansion offsets underlying Medicaid enrollment attrition. The scenario would be disconfirmed if Medicaid medical care ratios fail to improve in upcoming fiscal quarters or if individual exchange losses persist, which would become visible through state rate filings and quarterly statutory disclosures.
A quarterly earnings beat driven by accelerated state rate updates or faster elimination of individual exchange losses would confirm the underlying recovery trajectory. However, because the shares trade at $209.19 at a substantial premium over $153.64 and above $188.58, even an operational beat does not provide sufficient margin of safety to alter our defensive rating.
Meeting expectations demonstrates that management is executing on its cost controls and product exits. However, with the market price at $209.19 reflecting full multi-year normalization, matching guidance leaves shares vulnerable to the negative return implied by $153.64.
An operational earnings miss would demonstrate that the rate-trend deficit is widening and that adverse selection in pruned exchange books is worsening. This would impair projected earnings recovery and push fair value toward conservative downside boundaries.
Molina Healthcare exhibits mixed underlying earnings quality characteristic of regulated health maintenance organizations navigating an underwriting cycle. Reported GAAP net income diverges from operating cash flow due to timing differences in state capitation payments, risk-adjustment settlements, and medical claims reserves. The company maintains prudent actuarial margins on claims reserves for newly won business, which provides a conservative accounting buffer for future periods. However, recent earnings have been distorted by prior-period development and underwriting losses in commercial exchange products. A sustainable recovery in earnings quality will require positive operating cash flow conversion and normalization of core underwriting margins across state programs without relying on prior-year reserve adjustments.
Consensus earnings and revenue estimates have consolidated following recent management disclosures, with forward expectations for FY2026 reflecting guided trough profitability and FY2027 reflecting anticipated recovery from product exits and rate adjustments.
Demonstrates whether state capitation rate updates are successfully closing the gap with medical cost trends, directly governing the trajectory of consolidated operating margin normalization.
Molina's cash flow profile reflects regulated insurance dynamics, where working capital fluctuates based on timing of state capitation remittances, risk-adjustment accruals, and claims settlements. In FY2025, operating cash flow turned negative at -$535M despite GAAP net income of $472M, resulting in free cash flow of -$636M after capex of $101M. For FY2026, cash generation is rebounding, with parent company cash holding at $300M and projected to reach $600M by year-end on statutory subsidiary dividend distributions. Balance sheet liquidity remains sound, with stockholders' equity of $4.07B against long-term debt of $3.77B as of Q2 2026.56
Return on invested capital is positioned to rebound from cyclical trough levels in FY2026 as operating margin recovers from 1.6% toward normalized target levels of 3.0% to 3.2% by FY2029-FY2030, in line with managed care industry benchmarks of 3.0%. In FY2025, operating income was $781M on revenue of $45.43B (operating margin of 1.72%).
Normalized ROIC exceeds the moderate cost of equity of 8.66% (WACC of 7.64%), creating positive economic value as earnings recover toward consensus FY2027 EPS of $8.55.
| Doanh thu | 45.426.000.000 US$ |
|---|---|
| Giá vốn doanh thu | 41.351.000.000 US$ |
| Lợi nhuận gộp | 4.075.000.000 US$ |
| Chi phí hoạt động | 3.294.000.000 US$ |
| Lợi nhuận hoạt động | 781.000.000 US$ |
| Các khoản ngoài hoạt động và thuế | -309.000.000 US$ |
| Lợi nhuận ròng | 472.000.000 US$ |
| Tổng tài sản | 15.564.000.000 US$ |
|---|---|
| Tiền mặt | 4.248.000.000 US$ |
| Tài sản ngắn hạn | 12.444.000.000 US$ |
| Tổng nợ phải trả | 11.495.000.000 US$ |
| Nợ ngắn hạn | 7.372.000.000 US$ |
| Vốn chủ sở hữu | 4.069.000.000 US$ |
| Lợi nhuận ròng | 1.179.000.000 US$ |
|---|---|
| Dòng tiền vào từ hoạt động | 1.481.000.000 US$ |
| Khấu hao và phân bổ | 186.000.000 US$ |
| Thù lao bằng cổ phiếu | 116.000.000 US$ |
| Dòng tiền hoạt động | 644.000.000 US$ |
| Dòng tiền ra từ hoạt động | 837.000.000 US$ |
| Tiền sẵn có | 5.552.000.000 US$ |
| Tiền đầu kỳ | 4.908.000.000 US$ |
| Dòng tiền ra từ đầu tư | 464.000.000 US$ |
| Capex | 100.000.000 US$ |
| Hoạt động đầu tư khác | 364.000.000 US$ |
| Dòng tiền ra từ tài chính | 347.000.000 US$ |
| Phát hành nợ ròng | 740.000.000 US$ |
| Mua lại cổ phiếu | 1.000.000.000 US$ |
| Hoạt động tài chính khác | 87.000.000 US$ |
| Tiền cuối kỳ | 4.741.000.000 US$ |
| Dòng tiền đầu tư | -464.000.000 US$ |
| Dòng tiền tài chính | -347.000.000 US$ |
Dữ liệu tài chính tại thời điểm được dùng trong phân tích ngày 2026-10-14.
| Kỳ | Doanh thu | EBITDA | Lợi nhuận ròng | Dòng tiền hoạt động | Dòng tiền tự do | Capex | Khấu hao và phân bổ | Thù lao bằng cổ phiếu | Mua lại cổ phiếu | Cổ tức đã trả | Phát hành nợ ròng | Dòng tiền đầu tư | Dòng tiền tài chính | Tiền đầu kỳ | Tiền cuối kỳ | Tiền mặt và đầu tư | Tổng nợ | Biên hoạt động | ROIC | WACC | Chênh lệch ROIC−WACC |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2016-12-31 | 17,8 T US$ | 488 Tr US$ | 52 Tr US$ | 673 Tr US$ | 497 Tr US$ | 176 Tr US$ | 182 Tr US$ | 26 Tr US$ | — | 0 US$ | — | -206 Tr US$ | 19 Tr US$ | — | 2,9 T US$ | 4,6 T US$ | 1,4 T US$ | 1,7% | — | 5,3% | — |
| 2017-12-31 | 19,9 T US$ | -316 Tr US$ | -512 Tr US$ | 804 Tr US$ | 718 Tr US$ | 86 Tr US$ | 178 Tr US$ | 46 Tr US$ | 0 US$ | 0 US$ | — | -1,1 T US$ | 636 Tr US$ | 2,9 T US$ | 3,3 T US$ | 5,7 T US$ | 2,2 T US$ | -2,8% | — | — | — |
| 2018-12-31 | 18,9 T US$ | 1,2 T US$ | 707 Tr US$ | -314 Tr US$ | -344 Tr US$ | 30 Tr US$ | 127 Tr US$ | 27 Tr US$ | 0 US$ | — | — | 1,1 T US$ | -1,2 T US$ | 3,3 T US$ | 2,9 T US$ | 4,5 T US$ | 1,5 T US$ | 6,0% | — | 7,0% | — |
| 2019-12-31 | 16,8 T US$ | 1,1 T US$ | 737 Tr US$ | 434 Tr US$ | 377 Tr US$ | 57 Tr US$ | 89 Tr US$ | 39 Tr US$ | 47 Tr US$ | — | — | -293 Tr US$ | -559 Tr US$ | 2,9 T US$ | 2,5 T US$ | 4,4 T US$ | 1,5 T US$ | 6,2% | — | 5,9% | — |
| 2020-12-31 | 19,4 T US$ | 1,2 T US$ | 673 Tr US$ | 1,9 T US$ | 1,8 T US$ | 74 Tr US$ | 88 Tr US$ | 57 Tr US$ | 606 Tr US$ | — | — | -400 Tr US$ | 217 Tr US$ | 2,5 T US$ | 4,2 T US$ | 6 T US$ | 4,8 T US$ | 5,6% | — | 3,5% | — |
| 2021-12-31 | 27,8 T US$ | 1,1 T US$ | 659 Tr US$ | 2,1 T US$ | 2 T US$ | 77 Tr US$ | 131 Tr US$ | 72 Tr US$ | 128 Tr US$ | — | — | -1,7 T US$ | -183 Tr US$ | 4,2 T US$ | 4,5 T US$ | 7,6 T US$ | 2,4 T US$ | 3,7% | — | 4,5% | — |
| 2022-12-31 | 32 T US$ | 1,3 T US$ | 792 Tr US$ | 773 Tr US$ | 682 Tr US$ | 91 Tr US$ | 176 Tr US$ | 103 Tr US$ | 400 Tr US$ | — | 0 US$ | -790 Tr US$ | -441 Tr US$ | 4,5 T US$ | 4 T US$ | 7,5 T US$ | 2,4 T US$ | 3,7% | — | 6,8% | — |
| 2023-12-31 | 34,1 T US$ | 1,7 T US$ | 1,1 T US$ | 1,7 T US$ | 1,6 T US$ | 84 Tr US$ | 171 Tr US$ | 115 Tr US$ | 0 US$ | — | 0 US$ | -744 Tr US$ | -58 Tr US$ | 4 T US$ | 4,9 T US$ | 9,1 T US$ | 2,4 T US$ | 4,6% | — | 6,2% | — |
| 2024-12-31 | 40,7 T US$ | 1,9 T US$ | 1,2 T US$ | 644 Tr US$ | 544 Tr US$ | 100 Tr US$ | 186 Tr US$ | 116 Tr US$ | 1 T US$ | — | 740 Tr US$ | -464 Tr US$ | -347 Tr US$ | 4,9 T US$ | 4,7 T US$ | 9 T US$ | 3,1 T US$ | 4,2% | — | 6,5% | — |
| 2025-12-31 | 45,4 T US$ | 976 Tr US$ | 472 Tr US$ | -535 Tr US$ | -636 Tr US$ | 101 Tr US$ | 195 Tr US$ | 47 Tr US$ | 1 T US$ | — | 838 Tr US$ | 312 Tr US$ | -170 Tr US$ | 4,7 T US$ | 4,3 T US$ | 8,3 T US$ | 4 T US$ | 1,7% | — | 5,2% | — |
Molina Healthcare Inc. (MOH) trades at 18.9x forward earnings against a peer median of 12.3x. Its EV/EBITDA of 15.3x compares with a peer median of 10.4x. The comparison uses 4 peers: Humana Inc., The Cigna Group, Elevance Health Inc. and CVS Health Corporation, as of 2026-10-14.
The managed care sector is currently at an earnings and margin trough. Molina guides full-year 2026 Medicaid pretax operating margins to 1.2% and reaffirmed rate updates at 4% lagging 5% medical cost trends. Industry capital intensity remains disciplined, with industry capex-to-revenue at 0.9% and industry capex-to-depreciation at 0.81, while Molina's FY2025 capex of $101M on $45.43B revenue represents capex-to-revenue of 0.22% and capex-to-depreciation of 0.52 ($101M capex / $195M depreciation).57
In an industry upcycle, state Medicaid agencies grant generous prospective capitation rate increases that exceed medical loss trends, Medicaid redetermination attrition reverses into net membership gains, individual exchange enrollment expands profitably, and commercial peers avoid aggressive procurement price discounting.
In a managed care downcycle, medical cost inflation (specialty pharmacy, outpatient utilization, and behavioral health) persistently exceeds state rate adjustments, post-redetermination enrollment declines contract the total addressable market, and competitive procurement bidding erodes underwriting margins toward breakeven.
Molina is positioned as a specialized, low-overhead government program operator. While commercial giants such as CVS (forward P/E 10.26x), Cigna (forward P/E 8.44x), and Elevance Health (forward P/E 14.37x) maintain broader commercial books, Molina's pure-play government focus provides direct operating leverage to Medicaid rate recovery, balanced by high geographic concentration in approximately six core states.35
Under our Sell rating, a zero position allocation (0%) is recommended for long investors. At USD 209.19 as of 2026-10-14, Molina shares trade at a 36.2% premium over our Fair value of USD 153.64. The risk-reward profile is unfavorable, offering no margin of safety against potential execution failures or rate-setting delays.4
Risk management for Molina Healthcare centers on monitoring regulatory rate lag, medical cost inflation, and state procurement cycles. Investors must enforce strict portfolio discipline, recognizing that managed care organizations operate with high financial and operating leverage on razor-thin operating margins (1.2% Medicaid margin in FY2026). Unhedged long exposure at a 36.2% premium over Fair value of USD 153.64 carries severe downside risk. Institutional investors should reallocate capital toward more diversified managed care peers with defensive valuations and established dividend yields.
Trading at an extended premium to Fair value of USD 153.64, the stock offers inadequate compensation for state regulatory risk, contract re-bidding uncertainty, and long-term membership attrition.
Underweight Molina relative to diversified commercial MCOs, as peer valuations like Cigna at 8.44x forward P/E provide significantly better downside protection and cash dividend yields.3
Despite second-quarter stabilization, upcoming RFP contract filings and rate renegotiation deadlines present negative asymmetry without a compelling fundamental catalyst.
We recommend a Sell on Molina Healthcare Inc. At USD 209.19 as of 2026-10-14, the stock trades at an implied negative return of -26.6% to our Fair value of USD 153.64 and sits well above our Potential value of USD 188.58.4
While management is addressing cyclical headwinds by exiting unprofitable products and restructuring exchanges, market pricing already discounts a complete and rapid margin recovery, leaving shares highly vulnerable to ongoing 100 bps rate deficits, exchange adverse selection, and an 8% to 9% cumulative contraction in Medicaid lives.
Capture your own thesis, position size, and follow-up questions. Stays on this device, only you can see it.
The records this analysis drew on, as they stood when it was run.
Not every cited input appears here: internal calculations and intermediate model outputs have no external record, and some citations could not be matched to one.
Management acknowledged 30% price increases retained high-utilization members, and medical expenses are not risk-adjustable. Persistent adverse selection could keep underwriting losses above -$0.50/share into FY2027, preventing post-trough earnings normalization.5
Management highlighted an ongoing 8% to 9% cumulative market decline in Medicaid lives and footprint concentration into approximately six states. Loss of a major state Medicaid contract renewal combined with post-redetermination attrition accelerates enrollment runoff, reducing 5-year revenue growth by 5 percentage points.5
Diversified commercial peers Cigna and CVS Health trade at forward price-to-earnings multiples of 8.44x and 10.26x, respectively. As state Medicaid margin caps and procurement friction compress long-term return on capital, Molina's valuation multiple could permanently compress toward peer levels.3
Confirms that 30% price increases have caused structural adverse selection by retaining sicker, non-risk-adjustable members, delaying earnings normalization.
Hiện tại:-$0.75 per share guided for FY2026
Cảnh báo nếuLoss exceeding -$0.50 per share in FY2027
Demonstrates that enrollment runoff is accelerating beyond redetermination normalization, compressing fixed operating cost absorption against the 6.4% administrative ratio target.
Hiện tại:8% to 9% cumulative three-year industry decline
Cảnh báo nếuAnnual organic Medicaid revenue growth below 1.0%
Indicates persistent working capital drag from state reimbursement and risk adjustment settlement timing, impairing parent cash generation above the guided $600M year-end target.
Hiện tại:-$535M in FY2025
Cảnh báo nếuNegative operating cash flow for a second consecutive fiscal year
Erodes margin outperformance in Medicare duals ($1.25 EPS contribution on $5B revenue), removing the critical operational hedge against Medicaid enrollment contraction.
Hiện tại:4.0% in FY2026 (favorable vs 6.0% initial forecast)
Cảnh báo nếuDuals medical cost trend accelerating above 5.5%
| high |
| 6 to 18 months |
| Active engagement with state actuaries, contractual retroactive rate adjustments, and geographical diversification across more than 13 state markets.5 |
Under the moderate discount rate, 32,69 US$ comes from forecast-period earnings and 139 US$ from the long-term value, totaling 172 US$.
Project EPS through the explicit advantage period, fade growth as competition catches up, and discount the full stream at cost of equity.
Apply a terminal P/E to the dated forward EPS path, then discount that future share value back to the analysis date.
Add depreciation to net income, subtract maintenance capex, divide by diluted shares, and apply a normalized valuation multiple.
Solve for the growth rate that makes the model value equal the report-date share price.
Multiply the peer median PEG by this stock's forecast growth to derive an implied forward P/E, then apply it to forward EPS.
Our Bull scenario projects Potential value of $188.58, representing an implied return of -9.9% from $209.19 with an assigned probability of 20.0%. This upside pathway requires accelerated state rate updates that rapidly restore Medicaid pretax margins above targeted thresholds, complete elimination of exchange underwriting deficits, and aggressive top-line compounding driven by major state contract procurement wins and dual-eligible outperformance. This scenario would be disconfirmed if state procurement renewal awards are delayed, if competing commercial plans undercut pricing, or if medical cost trends accelerate in high-acuity populations.
Measures whether dramatic average price increases and geographic footprint reduction into core states successfully eliminate exchange drag without retaining disproportionately high-cost lives.
Determines whether favorable loss trends in specialized high-acuity Medicare programs continue to exceed expectations, offsetting broader Medicaid enrollment attrition.
Confirms the statutory cash conversion of health plan subsidiaries and dictates parent liquidity available for discretionary capital deployment and balance-sheet flexibility.
| $51.16B |
| $54.23B |
| $56.95B |
| Operating income | $711.32M | $1.06B | $1.38B | $1.63B | $1.82B |
| NOPAT | $535.56M | $795.74M | $1.04B | $1.22B | $1.37B |
| Residual cash after reinvestment policy | $482.00M | $716.17M | $936.07M | $1.10B | $1.23B |
| Revenue growth | -2.1% | 8.1% | 6.5% | 6.0% | 5.0% |
| Operating margin | 1.6% | 2.2% | 2.7% | 3.0% | 3.2% |
| Tax rate | 24.7% | 24.7% | 24.7% | 24.7% | 24.7% |
| Reinvestment rate | 10.0% | 10.0% | 10.0% | 10.0% | 10.0% |
| Terminal growth | 2.5% | 2.5% | 2.5% | 2.5% | 2.5% |
Molina allocates capital primarily toward regulatory capital requirements at its insurance subsidiaries, followed by bolt-on state Medicaid plan acquisitions and opportunistic share repurchases. Because Molina does not pay a common dividend, capital return relies on share buybacks funded by statutory dividend flows up to the parent company. Management expects parent cash to rise from $300M to $600M by the end of 2026, providing flexibility to repurchase shares or support state contract procurements once operating cash flow normalizes.
Medicaid pretax operating margin is guided to 1.2% in FY2026 with a medical care ratio of 92.9% as 4% rate updates trail 5% medical cost trends.
Underwriting profitability has reached cyclical lows; closing the 90 bps margin gap back toward 2.5% provides the primary operational driver for post-FY2026 earnings expansion.
Exiting discontinued Medicare Advantage MAPD removes a $1.00 per share loss, while pruning the Marketplace footprint into 6 states targets elimination of a $0.75 per share drag.
Removing $1.75 per share of cumulative non-recurring losses bridges FY2026 trough earnings of $5.25 toward consensus FY2027 EPS of $8.55 without requiring substantial organic volume expansion.
Medicare duals generates $5B in revenue and contributes $1.25 per share in earnings, driven by medical cost trends performing at 4% versus 6% initially expected.
High-margin duals growth offsets industry-wide Medicaid enrollment contraction of 8% to 9% and supports top-line expansion toward $48.04B consensus revenue in FY2027.
| Biên |
|---|
| MOH | Molina Healthcare Inc. | $10.9B | 18.9x | 0.3x | 15.3x | -0.2% | — |
| HUM | Humana Inc. | $51.3B | 25.8x | 0.4x | 11.5x | 6.9% | 3.5% |
| CI | The Cigna Group | $74.7B | 8.4x | 0.3x | 7.8x | 16.8% | 4.0% |
| ELV | Elevance Health Inc. | $92.2B | 14.4x | 0.5x | 10.3x | 11.1% | 4.6% |
| CVS | CVS Health Corporation | $112.0B | 10.3x | 0.3x | 10.5x | 6.2% | 3.9% |
| The multi-year unwinding of continuous enrollment provisions has led to an 8% to 9% cumulative reduction in Medicaid lives across the industry, leaving a sicker remaining member pool. |
| Specialty Pharmacy and GLP-1 High-Cost Drug Utilization | negative | Rapid adoption of high-cost specialty therapeutics and pharmaceuticals creates cost pressure that is not immediately offset by risk-adjustment mechanisms in government programs. |
| Represents deep value territory pricing in prolonged underwriting deficits, offering favorable asymmetry if subsidiary dividend extractions remain intact. |
| Parent Company Cash Liquidity | Parent cash balance failing to reach $600M by year-end 2026 | Flag restricted subsidiary dividend flows and reassess capital return capacity. |
| State Medicaid Contract Renewals | Loss of an incumbent contract in any of the six core operating states | Immediately cut medium-term revenue CAGR by 300 to 500 basis points and re-evaluate franchise durability. |
